Latest StemCells Inc. Stories
Editor Note: For more information about this release, please scroll to bottom. LONDON, May 16, 2014 /PRNewswire/ -- The US markets saw a negative sentiment on Thursday,
Editor Note: For more information about this release, please scroll to bottom. LONDON, March 24, 2014 /PRNewswire/ -- On Friday, March 20, 2014, the NASDAQ Composite
MarketResearch.com announces the addition of a new market research report in Biotechnology to their product offering:Regenerative Medicine Markets; http://www.marketresearch.com/land/product.asp?productid=7458272&progid=85536
New findings demonstrate potential to treat a wide variety of disorders that affect myelin
In a month, where the Pennsylvania Association for the Blind is creating awareness on Age-Related Macular Degeneration (AMD,) drug researcher StemCells Inc.
StemCells Inc has filed for Swiss regulatory approval for clinical trials of its nerve stem cells in patients with spinal cord injuries, the company said.
A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells.
StemCells, Inc. (Nasdaq:STEM) announced today that results pertaining to the Company's research programs in retinal degeneration as well as spinal cord injury will be presented at the Society for Neuroscience Annual Meeting scheduled for November 15-19, 2008 in Washington, DC.
StemCells, Inc. (NASDAQ:STEM) announced today that it has entered into agreements to raise approximately $20 million in gross proceeds through the sale of approximately 13.8 million shares of its common stock to selected institutional investors at a price of $1.45 per share.
StemCells, Inc. (NASDAQ:STEM) reported today that its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells), when transplanted into a well-established animal model, can protect the retina from progressive degeneration.